Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Browse Trials by Condition
- Neoplasms 18,336
- Lymphocytic Leukemia, Acute 15,317
- Muscular Dystrophy 15,154
- Metastatic Cancer 10,936
- Neoplasm Metastasis 10,819
- Menstruation 8,794
- Surgery 8,770
- Carcinoma 6,658
- Uterine Fibroids 6,571
- Neurologic Disorders 6,499
- Pain 5,897
- Chemotherapy 5,309
- Wounds 4,979
- Lung Disease 4,726
- Allergy 4,144
- Vascular Diseases 3,926
- Vision Loss 3,750
- Heart Disease 3,222
- Cardiac Disease 3,207
- Depression 3,050
- Inflammation 2,894
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
You are in great company.
Institutes that trust us.
New & updated studies
Browse all studies
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: Sacituzumab govitecan (a type of antibody-drug conjugate) Trastuzumab (Herceptin) (a …
Communication Skills to Build a Diverse Biomedical Workforce
This trial investigates how receiving instruction in communication skills affects short and long-term career outcomes for students, postdoctoral fellows, and future faculty. This may help researchers learn more about the factors that may help or block career goals and career persistence of trainees.
A Trial to Learn How REGN5381 Works and How Safe it is in Adults With Heart Failure With Reduced Ejection Fraction (HFrEF)
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, your heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the …
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) …
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). In …
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (<300/mm3) without evidence of HIV infection or other known immunodeficiency. Patients with ICL are at risk for opportunistic infections typically associated with HIV/AIDS such as disseminated cryptococcal infection and severe human papillomavirus-related dysplasia. More …
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the trial and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial journey begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.